At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 14 enrolled
Drug / intervention
Vorinostatdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Pharmacokinetic and Biologic Correlative Study of Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Renal Cell Carcinoma (RCC)
In Brief
A Phase 2 clinical trial evaluating Vorinostat for Recurrent Renal Cell Carcinoma and Stage IV Renal Cell Cancer. Completed, enrolled 14 participants across 2 sites.
Detailed Summary
This phase II trial is studying how well vorinostat works in treating patients with advanced kidney cancer. Drugs used in chemotherapy, such as vorinostat, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vorinostat may also stop the growth of tumor cells by blocking blood flow to the tumor.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2005
First PostedJan 2006
Primary CompletionFeb 2010
TodayJul 2026
First PostedJan 18, 2006
Enrollment StartOct 1, 2005
Primary CompletionFeb 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 20.5 years ago
Interventions
Vorinostatdrug
Given orally